國立虎尾科技大學 |

Enhancing Health Policy Decisions in Diseases Affecting Disadvantaged Populations : = Applied and Methodological Analyses.

Record Type:	Language materials, manuscript : Monograph/item
Title/Author:	Enhancing Health Policy Decisions in Diseases Affecting Disadvantaged Populations :/
Reminder of title:	Applied and Methodological Analyses.
Author:	James, Lyndon.
Description:	1 online resource (198 pages)
Notes:	Source: Dissertations Abstracts International, Volume: 85-12, Section: B.
Contained By:	Dissertations Abstracts International85-12B.
Subject:	Health sciences. -
Online resource:	click for full text (PQDT)
ISBN:	9798382776101

Enhancing Health Policy Decisions in Diseases Affecting Disadvantaged Populations : = Applied and Methodological Analyses.
James, Lyndon.

Enhancing Health Policy Decisions in Diseases Affecting Disadvantaged Populations :Applied and Methodological Analyses. - 1 online resource (198 pages)

Source: Dissertations Abstracts International, Volume: 85-12, Section: B.

Thesis (Ph.D.)--Harvard University, 2024.

Includes bibliographical references

In this dissertation, I employed three different analytic lenses to help improve health policy decisions. Each chapter focuses on either tuberculosis (TB) or sickle cell disease (SCD), conditions which predominantly affect systematically disadvantaged populations. I investigated the effectiveness and cost-effectiveness of shorter, all-oral regimens to treat rifampicin-resistant TB (RR-TB) in Moldova-a country with a high burden of RR-TB-and explored the impact of methodological decisions on the distributional (i.e., equity-weighted) cost-effectiveness of new gene therapies for Sickle Cell Disease (SCD) in the United States (US).In chapter 1, I evaluated the cost-effectiveness and budget impact of a 6-month regimen of bedaquiline, pretomanid, linezolid and moxifloxacin (BPaLM) to treat pulmonary RR-TB in Moldova, as compared to established 9- to 18-month regimens. Using genomic data, I built a microsimulation model to estimate the quality-adjusted life expectancy and costs under each strategy, and tracked the evolution of resistance of M. tuberculosis to 12 anti-TB drugs. Compared to longer regimens, I found that 6 months of BPaLM was cost-effective across a broad range of scenarios, and would save Moldova's national TB program budget $7.1 million (95% UI: [1.3 million, 15.4 million]) over the five year period from implementation. Six months of BPaLM also reduced the length of time spent with TB resistant to six drugs (including bedaquiline and moxifloxacin), while it increased the time spent with TB resistant to two drugs (delamanid and pretomanid), findings which could exert additional spillover effects. Overall, this study adds to the growing body of evidence in favor of shorter, more tolerable, all-oral regimens for RR-TB.In chapter 2, I compared the effectiveness of all-oral bedaquiline-containing regimens against injectable-containing regimens for pulmonary RR-TB in Moldova using data from routinely collected electronic medical records. In an intention-to-treat analysis of a cohort of adults initiating treatment for culture-positive RR-TB in 2019-2021, I found that all-oral bedaquiline-containing regimens were associated with improved probability and hazard rate of culture conversion in 6 months following treatment initiation, after adjusting for baseline covariates. These results contribute to both clinical and policy decisions alongside other empirical and modeling evidence on the tolerability, long-term health outcomes, and cost-effectiveness of these regimens.In chapter 3, I explored the impact of methodological decisions within distributional cost-effectiveness analysis (DCEA). DCEA is a modeling approach capable of balancing concerns for efficiency and equity, by affording extra priority to groups who are less well-off. Although interest is growing in applying these methods, guidance for conducting DCEA in the US setting is limited. Using an applied example in SCD, I modeled the US population in 2023, and showed that the choice of variables used to stratify the population into equity-relevant groups can affect whether a new SCD gene therapy would be recommended, even while holding the level of inequality aversion constant. Results may also be impacted by cost incidence assumptions, specifically as to how opportunity costs are experienced by those enrolled in Medicaid. This work highlights the need for awareness of the normative implications of modeling decisions in DCEA, and for reaching consensus on how these analyses are conducted in the US.

Electronic reproduction.
Ann Arbor, Mich. :
ProQuest,
2024

Mode of access: World Wide Web

ISBN: 9798382776101Subjects--Topical Terms:

1179212
Health sciences.
Subjects--Index Terms:

Decision analysisIndex Terms--Genre/Form:

554714
Electronic books.

Enhancing Health Policy Decisions in Diseases Affecting Disadvantaged Populations : = Applied and Methodological Analyses.
LDR:05007ntm a22004217 4500 001 1151574
005 20241112095355.5
006 m o d
007 cr mn ---uuuuu
008 250605s2024 xx obm 000 0 eng d
020 $a 9798382776101
035 $a (MiAaPQ)AAI31296478
035 $a AAI31296478
040 $a MiAaPQ $b eng $c MiAaPQ $d NTU
100 1 $a James, Lyndon. $3 1478372
245 1 0 $a Enhancing Health Policy Decisions in Diseases Affecting Disadvantaged Populations : $b Applied and Methodological Analyses.
264 0 $c 2024
300 $a 1 online resource (198 pages)
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
500 $a Source: Dissertations Abstracts International, Volume: 85-12, Section: B.
500 $a Advisor: Menzies, Nicolas.
502 $a Thesis (Ph.D.)--Harvard University, 2024.
504 $a Includes bibliographical references
520 $a In this dissertation, I employed three different analytic lenses to help improve health policy decisions. Each chapter focuses on either tuberculosis (TB) or sickle cell disease (SCD), conditions which predominantly affect systematically disadvantaged populations. I investigated the effectiveness and cost-effectiveness of shorter, all-oral regimens to treat rifampicin-resistant TB (RR-TB) in Moldova-a country with a high burden of RR-TB-and explored the impact of methodological decisions on the distributional (i.e., equity-weighted) cost-effectiveness of new gene therapies for Sickle Cell Disease (SCD) in the United States (US).In chapter 1, I evaluated the cost-effectiveness and budget impact of a 6-month regimen of bedaquiline, pretomanid, linezolid and moxifloxacin (BPaLM) to treat pulmonary RR-TB in Moldova, as compared to established 9- to 18-month regimens. Using genomic data, I built a microsimulation model to estimate the quality-adjusted life expectancy and costs under each strategy, and tracked the evolution of resistance of M. tuberculosis to 12 anti-TB drugs. Compared to longer regimens, I found that 6 months of BPaLM was cost-effective across a broad range of scenarios, and would save Moldova's national TB program budget $7.1 million (95% UI: [1.3 million, 15.4 million]) over the five year period from implementation. Six months of BPaLM also reduced the length of time spent with TB resistant to six drugs (including bedaquiline and moxifloxacin), while it increased the time spent with TB resistant to two drugs (delamanid and pretomanid), findings which could exert additional spillover effects. Overall, this study adds to the growing body of evidence in favor of shorter, more tolerable, all-oral regimens for RR-TB.In chapter 2, I compared the effectiveness of all-oral bedaquiline-containing regimens against injectable-containing regimens for pulmonary RR-TB in Moldova using data from routinely collected electronic medical records. In an intention-to-treat analysis of a cohort of adults initiating treatment for culture-positive RR-TB in 2019-2021, I found that all-oral bedaquiline-containing regimens were associated with improved probability and hazard rate of culture conversion in 6 months following treatment initiation, after adjusting for baseline covariates. These results contribute to both clinical and policy decisions alongside other empirical and modeling evidence on the tolerability, long-term health outcomes, and cost-effectiveness of these regimens.In chapter 3, I explored the impact of methodological decisions within distributional cost-effectiveness analysis (DCEA). DCEA is a modeling approach capable of balancing concerns for efficiency and equity, by affording extra priority to groups who are less well-off. Although interest is growing in applying these methods, guidance for conducting DCEA in the US setting is limited. Using an applied example in SCD, I modeled the US population in 2023, and showed that the choice of variables used to stratify the population into equity-relevant groups can affect whether a new SCD gene therapy would be recommended, even while holding the level of inequality aversion constant. Results may also be impacted by cost incidence assumptions, specifically as to how opportunity costs are experienced by those enrolled in Medicaid. This work highlights the need for awareness of the normative implications of modeling decisions in DCEA, and for reaching consensus on how these analyses are conducted in the US.
533 $a Electronic reproduction. $b Ann Arbor, Mich. : $c ProQuest, $d 2024
538 $a Mode of access: World Wide Web
650 4 $a Health sciences. $3 1179212
650 4 $a Public policy. $3 1002398
650 4 $a Public health. $3 560998
650 4 $a Medicine. $3 644133
650 4 $a Epidemiology. $3 635923
653 $a Decision analysis
653 $a Decision science
653 $a Distributional cost-effectiveness analysis
653 $a Tuberculosis
653 $a Health policy decisions
655 7 $a Electronic books. $2 local $3 554714
690 $a 0566
690 $a 0630
690 $a 0564
690 $a 0766
690 $a 0573
710 2 $a ProQuest Information and Learning Co. $3 1178819
710 2 $a Harvard University. $b Health Policy. $3 1478373
773 0 $t Dissertations Abstracts International $g 85-12B.
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=31296478 $z click for full text (PQDT)